Oxaliplatin plus capecitabine for advanced gastric cancer: report of 38 cases.
- Author:
Mei GUAN
1
;
Lu ZHANG
;
Lin ZHAO
;
Chun-mei BAI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Capecitabine; Deoxycytidine; administration & dosage; analogs & derivatives; therapeutic use; Female; Fluorouracil; administration & dosage; analogs & derivatives; therapeutic use; Humans; Male; Middle Aged; Organoplatinum Compounds; administration & dosage; Retrospective Studies; Stomach Neoplasms; drug therapy; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2010;32(4):407-411
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of the combination chemotherapy of oxaliplatin with capecitabine(XELOX)in patients with advanced gastric cancer.
METHODSThirty-eight advanced gastric cancer patients who received XELOX regimen during 2004-2009 were analyzed retrospectively. The combination chemotherapy included oxaliplatin as 2-hour infusion on day 1 and capecitabine po bid on days 1 to 14. Treatment was repeated every 3 weeks.
RESULTSXELOX regime was applied as first-line therapy in 34 patients and as second-line therapy in 4 patients. After three cycles of chemotherapy, the outcomes in 32 patients who received XELOX as the first-line therapy included partial response (n = 8,25.0%), stable disease (n=14,43.8%), and progressive disease (n=10, 31.2%); no patient achieved complete response. The median time to progression and overall survival time were 7.0 months (95% CI: 4.5-9.5 months) and 12 months (95% CI: 9.8-14.2 months), respectively. One-year and two-year survival rates were 40.6% and 23.7%, respectively. Grade 3-4 toxicities including neutropenia (10.5%), thrombocytopenia (2.6%), nausea (7.9%), and vomiting (5.3%)were noted in a few patients.
CONCLUSIONXELOX regimen can be effectively and safely applied as first-line treatment for advanced gastric cancer patients.
